Condition
Rosacea Subtype 1 (Erythematotelangiectatic)
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 4 (1)
Trial Status
Completed3
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07521462Not ApplicableNot Yet Recruiting
Dermocosmetic Treatment for Facial Redness in Rosacea With or Without Laser Therapy
NCT07431476Phase 4Completed
Brimonidine 0.33% for Rosacea-Related Facial Erythema
NCT06776445Phase 1Completed
Efficacy and Safety of Different Dose Regimens of Gabapentin for Treating Erythema/Flushing in Rosacea: A Randomized Controlled Trial
NCT01666509Not ApplicableCompletedPrimary
Efficacy and Tolerability of Topical Rossoseq™ Compared to Vehicle in Rosacea Subtype 1 (Erythematotelangiectatic)
Showing all 4 trials